REGENERON PHARMACEUTICALS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 19 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-09-02: Reporting owner Guarini Kathryn; Form 4; Security Non-Qualified Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-19: Reporting owner LAROSA JOSEPH J; Form 4; Security Non-Qualified Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-18: Reporting owner Fenimore Christopher R.; Form 4; Security Non-Qualified Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-10: Reporting owner Guarini Kathryn; Form 4; Security Non-Qualified Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
REGN insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-02 | Guarini Kathryn Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −400 1,158 owned after | $719.37 exercise price | $852.03 | 2026-09-03 |
| 2026-08-19 | LAROSA JOSEPH J Officer (EVP General Counsel and Secret) | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,282 12,283 owned after | $381.92 exercise price | $840.84 | 2026-08-21 |
| 2026-08-18 | Fenimore Christopher R. Officer (EVP Finance CFO) | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,283 6,000 owned after | $381.92 exercise price | $810.24 | 2026-08-20 |
| 2026-08-10 | Guarini Kathryn Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −400 1,558 owned after | $719.37 exercise price | $808.05 | 2026-08-12 |
| 2026-08-10 | Zoghbi Huda Y Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −800 0 owned after | $376.69 exercise price | $808.05 | 2026-08-12 |
| 2026-02-19 | Zoghbi Huda Y Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,638 800 owned after | $376.69 exercise price | $782.38 | 2026-02-23 |
| 2026-02-09 | Pitofsky Jason Officer (SVP Controller) | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,000 905 owned after | $492.00 exercise price | $780.28 | 2026-02-11 |
| 2026-01-07 | Bassler Bonnie L Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 2,861 owned after | $374.12 exercise price | $812.27 | 2026-01-08 |
| 2026-01-02 | Zoghbi Huda Y Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | Thompson Craig B. Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | SING GEORGE L Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | Guarini Kathryn Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | Schenkein David P Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | GOLDSTEIN JOSEPH L Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | RYAN ARTHUR F Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | COLES N ANTHONY Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | BROWN MICHAEL S Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | Bassler Bonnie L Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
| 2026-01-02 | POON CHRISTINE A Director | 4 | Non-Qualified Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,962 1,962 owned after | $772.76 exercise price | $776.31 | 2026-01-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |